Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Prometheus Biosciences, Inc. is a biotechnology company focused on developing precision medicines for patients with autoimmune diseases, particularly through its proprietary monoclonal antibody therapies. Its unique competitive position is bolstered by a robust pipeline, including the lead asset, PRA023, which targets ulcerative colitis and Crohn's disease, with promising clinical trial results driving investor interest.
Prometheus generates revenue through the development and commercialization of its monoclonal antibody therapies. The company has a high gross margin due to the nature of biotech products, but currently operates at a significant loss as it invests heavily in R&D. Its competitive advantage lies in its precision medicine approach, which allows for tailored treatments based on genetic and biomarker profiles.
Clinical trial results for PRA023 and other pipeline candidates
Regulatory approvals from the FDA or EMA
Partnership announcements or collaborations with larger pharmaceutical companies
Market adoption rates of approved therapies
Regulatory changes affecting drug approval processes
Technological disruption in biotech that could render existing therapies obsolete
Emergence of competing therapies targeting the same autoimmune conditions
Potential for larger pharmaceutical companies to outspend on R&D
High cash burn rate leading to potential liquidity issues if funding is not secured
Dependence on successful clinical trial outcomes to attract future investment
low - The demand for biotech therapies is less correlated with the economic cycle, as healthcare spending tends to remain stable even during downturns.
Moderate - Rising interest rates could increase the cost of capital for R&D financing, impacting the company's ability to fund its clinical trials and operations.
minimal - The company has low debt levels, with a Debt/Equity ratio of 0.04, indicating minimal reliance on credit.
growth - Investors are likely drawn to the high potential upside from successful drug development.
high - The stock has exhibited significant volatility, evidenced by a 576.5% return over the past year.
